AI, Diagnostics, and the Return of Strategic Excitement
Boston, April 3rd, 2026 — Yesterday, DeciBio co-hosted a dinner with Hunter Healthcare, bringing together ~20 executives and investors across life science tools, diagnostics, oncology services, and healthcare investing.
The conversation kept coming back to two themes: AI is becoming unavoidable, and diagnostics is "having a moment."
Not "a moment" in the frothy, hand-wavy sense. More like: the industry is beginning to recognize that diagnostics are not just a support function for therapeutics. They are increasingly becoming the operating layer for precision medicine.
We had a room that spanned the "full stack": companies building instruments, assays, data platforms, spatial and single-cell tools, oncology models, blood-based diagnostics, and investors trying to understand where durable value will accrue. That mix made the AI conversation much more grounded than the usual "will AI replace everyone by Tuesday?" debate.
The most interesting question was: where does AI actually create defensible value in tools and diagnostics? A few themes stood out.
First, AI is most powerful when it is attached to proprietary biology, workflow, or data. A general-purpose model may help write emails, summarize papers, or accelerate analysis, but the real strategic value in this sector comes when AI is embedded inside differentiated datasets, assays, clinical workflows, or decision points. In other words, the model is not the moat. The biology, data rights, workflow integration, and customer context often are.
Second, diagnostics companies are becoming more system-like. The winning platforms are not just selling a test. They are managing sample logistics, evidence generation, reimbursement, clinical reporting, physician education, pharma partnerships, and longitudinal data. That is hard to replicate. It is also exactly where AI can compound value over time.
Third, the center of gravity in precision medicine may be shifting. For years, therapeutics captured most of the strategic imagination. But if you want earlier detection, better patient selection, smarter monitoring, MRD, MCED, rare disease diagnosis, better trial enrollment, and more efficient healthcare delivery, the enabling layer is often diagnostics and tools.
That is why this moment feels different. AI is not replacing diagnostics. It is making the best diagnostics platforms more scalable, more interpretable, and potentially more embedded in care pathways. And diagnostics are giving AI something it desperately needs: high-value, clinically meaningful, biologically grounded data.
My takeaway from the dinner: the next few years will be about "AI-enabled precision medicine infrastructure." And that infrastructure will likely be built by the companies that understand both sides of the equation: the biology and the business model.
Thanks to Hunter Healthcare for helping convene such a thoughtful group. These are exactly the kinds of conversations the industry needs more of: interdisciplinary, candid, and grounded in what it will actually take to move precision medicine from promise to practice.